NCT06632977 2026-04-07
PREDICT
Alliance for Clinical Trials in Oncology
Phase 2 Recruiting
Clinical Trials
43 trialsNCT04709276 2026-04-06
CHAMP
Duke University
Phase 2 Active not recruiting
NCT03419234 2026-04-01
Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT01616875 2026-03-06
Bristol Bladder Trial
University Hospitals Bristol and Weston NHS Foundation Trust
Phase 2 Completed
NCT02703623 2026-03-06
Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03263650 2026-02-17
Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03556904 2026-01-15
FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE)
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT04592237 2025-12-23
Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT02985957 2025-12-22
CheckMate 650
Bristol-Myers Squibb
Phase 2 Completed
NCT06738303 2025-08-27
CATCH-177
Case Comprehensive Cancer Center
Phase 2 Recruiting
NCT05005728 2025-07-17
XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer
Xencor, Inc.
Phase 2 Completed
NCT01437488 2025-05-04
Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy
Thomas Jefferson University
Phase 2 Completed
NCT03764540 2025-04-13
CABPOSTAAT
Centre hospitalier de l'Université de Montréal (CHUM)
Phase 2 Terminated
NCT06890832 2025-03-24
A Study to Investigate Efficacy and Safety of Different Dose Regimen of Oral Cabazitaxel Tablet in Adult Participants with Prostate Cancer
Jina Pharmaceuticals Inc.
Phase 2 Not yet recruiting
NCT02218606 2024-12-10
Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in Treatment of Metastatic Castration Resistant Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT05762536 2024-06-27
DAROTAXEL
Erasmus Medical Center
Phase 2 Recruiting
NCT05563558 2024-06-11
PEAPOD_FOS
Fundacion Oncosur
Phase 2 Recruiting
NCT03934840 2024-02-28
CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone
Masonic Cancer Center, University of Minnesota
Phase 2 Active not recruiting
NCT02903160 2024-02-07
Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)
Icahn School of Medicine at Mount Sinai
Phase 2 Completed
NCT02478502 2024-02-02
Testis CAB: Cabazitaxel as Salvage Treatment for Cisplatin-resistant Germ Cell Cancer
University Hospital, Akershus
Phase 2 Terminated
NCT02543255 2024-01-31
ACDC-RP
University Health Network, Toronto
Phase 2 Completed
NCT04495179 2023-08-09
AARDVARC
AstraZeneca
Phase 2 Completed
NCT03114254 2022-11-18
JAVA-P
University Hospitals Bristol and Weston NHS Foundation Trust
Phase 2 Completed
NCT03392428 2022-06-13
TheraP
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Phase 2 Completed
NCT01650285 2022-03-04
Cabazitaxel and Radiation For Patients With Prostate Cancer
Brown University
Phase 2 Terminated
NCT03101046 2022-02-10
TACTIK
UNICANCER
Phase 2 Completed
NCT03050866 2021-08-20
CABA-V7
Erasmus Medical Center
Phase 2 Unknown
NCT02844582 2021-01-25
Cabazitaxel and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
University of California, Davis
Phase 2 Terminated
NCT04622761 2021-01-05
CHROME
The Clatterbridge Cancer Centre NHS Foundation Trust
Phase 2 Not yet recruiting
NCT02512458 2020-02-10
CABA-BONE
Hellenic Cooperative Oncology Group
Phase 2 Completed
NCT02379390 2019-06-21
PRIMCAB
Sanofi
Phase 2 Terminated
NCT01845792 2018-06-04
Study of Abiraterone Acetate and Prednisone in Combination With Cabazitaxel in Patients With Prostate Cancer
University of Colorado, Denver
Phase 2 Terminated
NCT03356912 2017-12-14
CABAzitaxel With or Without Prednisone in Patients With Metastatic CAstration REsistant Prostate Cancer Progressed During or After a Previous Docetaxel-based Chemotherapy
Consorzio Oncotech
Phase 2 Unknown
NCT02254785 2017-12-06
Cabazitaxel vs Abiraterone or Enzalutamide in Patients With Poor Prognosis Metastatic Castration-resistant Prostate Cancer
British Columbia Cancer Agency
Phase 2 Unknown
NCT01718353 2017-11-20
TAXYNERGY
Sanofi
Phase 2 Completed
NCT01518283 2017-07-02
Study of Weekly Cabazitaxel for Advanced Prostate Cancer
Spanish Oncology Genito-Urinary Group
Phase 2 Completed
NCT02621190 2016-08-17
CARVE
Erasmus Medical Center
Phase 2 Withdrawn
NCT01541007 2015-11-02
ConCab
Karolinska University Hospital
Phase 2 Completed
NCT01600339 2015-05-12
A Trial of Cabazitaxel for Advanced Transitional Cell Carcinoma (TCC)
Rambam Health Care Campus
Phase 2 Completed
NCT01469338 2014-11-24
Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel
University of Southern California
Phase 2 Terminated
NCT01531205 2014-11-05
Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT01576029 2013-12-24
SWITCH
Sanofi
Phase 2 Completed
NCT01750866 2013-10-16
Cabazitaxel in Men 75 Years of Age or Older With Castration-Resistant Prostate Cancer
Case Comprehensive Cancer Center
Phase 2 Withdrawn